m+Medelevator.RU
← Поиск публикаций
Ginekologia polska · 2026

Symptom reduction and safety profile of uterine artery embolization for symptomatic fibroids.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Krzyzanowski Jaroslaw, Paszkowski Tomasz, Szkodziak Piotr, Pyra Krzysztof, Krzyzanowski Arkadiusz, Sojka Michal, Knap Daniel, Wozniak Slawomir

Аннотация

OBJECTIVES: To assess long-term efficacy and safety of uterine artery embolization for symptomatic uterine fibroids.

MATERIAL AND METHODS: This retrospective cohort study included women undergoing uterine artery embolization for symptomatic fibroids from 2012 to 2023. A validated questionnaire assessed symptoms (e.g., heavy menstrual bleeding, pelvic pain) pre- and post- uterine artery embolization. Data on fibroid characteristics, follow-up duration, menopause status, and complications were collected. Patients were stratified into follow-up terciles. Statistical analyses included Wilcoxon signed-rank tests, linear regression with menopause adjustment, and Spearman correlations tests (p < 0.05).

RESULTS: Uterine artery embolization significantly reduced symptoms, particularly bleeding-related complaints, with sustained efficacy across short-, mid-, and long-term follow-up, even after menopause adjustment. Menopause enhanced symptom relief. No correlations were found between symptom reduction and age, fibroid size, or prior treatment. Complications, mostly minor, occurred in a notable proportion, with rare major events. A small subset achieved successful pregnancies post-embolization.

CONCLUSIONS: Uterine artery embolization is an effective, minimally invasive treatment for fibroid-related symptoms, with sustained benefits over time; menopause significantly predicts greater symptom improvement.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты